

# Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome

NCT07481422

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	University of Rijeka
Enrollment	70 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- years of age
- disease activity defined by an IBS-Symptom Severity Score (IBS-SSS) of more than 175
- symptoms refractory to conservative medical therapy (hyoscine salts, osmotic laxatives such as polyethylene glycol, loperamide, rifaximin, tricyclic antidepressants, SSRIs or other antidepressants, peppermint oil)
- negative evaluation for coeliac disease
- signed informed consent

### Exclusion (10)

- pregnant or breastfeeding women
- women of childbearing potential who are unwilling to use an acceptable method of birth control
- severely immunocompromised or immunosuppressed (organ transplant recipients, those with neutropenia with an absolute neutrophil count of  $<500$  cells per mm<sup>3</sup>, those receiving current treatment with antineoplastic drugs, HIV positive)
- gastrointestinal symptoms explained by an alternative diagnosis (underlying IBD, infectious enteritis)
- severe allergy to capsule components
- ... and 5 more (see full listing online)

## Locations (1 total)

---

Clinical Hospital Center Rijeka, Rijeka, Croatia